Q1 2025 Earnings Call Transcript May 14, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is ...

Analysts anticipate PDS Biotechnology to report an earnings per share (EPS) of $-0.22. The market awaits PDS Biotechnology's announcement, with hopes high for news of surpassing estimates and ...

EAST PRINCETON, N.J. (AP) — EAST PRINCETON, N.J. (AP) — PDS Biotechnology Corporation (PDSB) on Wednesday reported a loss of $8.5 million in its first quarter. On a per-share basis, the East Princeton ...

Greetings and welcome to the PDS Biotech first quarter in 2025 earnings conference call. (operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce ...

On April 23, 2025, the Company announced that three abstracts on Versamune® HPV (PDS0101) were selected for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to be ...

PDS Biotechnology Corp (PDSB) reports reduced net loss and strategic clinical trial progress, despite ongoing financial hurdles.

Henderson, Nev.-based PDS Health is implementing additional machine identity security solutions to its network across the U.S. The DSO is adding CyberArk’s Zero Touch PKI and Certificate Manager to ...

PDS Biotechnology Corporation’s PDSB share price has dipped by 5.76%, which has investors questioning if this is right time to buy.

NEWTON, Mass. & PETACH TIKVA, Israel--(BUSINESS WIRE)--CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced that PDS Health, a leading integrated healthcare support ...